Video Programs

In this final segment, Dr Luskin discusses treatment sequencing considerations in blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a focus on integrating targeted therapy and allogeneic stem cell transplantation.

Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with prior therapy in endometrial cancer.

This segment addresses the clinical implications of disease burden in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a condition that frequently presents with extensive skin involvement or other high-burden manifestations.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Endometrial cancer treatment evolves with molecular insights, enhancing patient outcomes through tailored therapies and innovative clinical trials.

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.

This segment focuses on safety considerations associated with tagraxofusp in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), with an emphasis on early toxicity recognition in community oncology settings

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a disease that predominantly affects older adults

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are steroid refractory/dependent. She also discusses treatment approaches and results with these agents in clinical trials and in real-world settings.

Design and Function of Oncodetect Assay for MRD Detection

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.

Explore the complexities of assessing chronic graft-versus-host disease severity and the role of NIH criteria in treatment decisions.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive testing and improved communication.

Dr. DeFilipp explores innovative strategies for managing chronic graft-versus-host disease, emphasizing personalized treatment and the shift towards targeted therapies.

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and education are vital for improvement.

Emergence and Evolution of ctDNA Assays for MRD in TNBC

TNBC Treatment and the Emergence of MRD Detection Assays

Discover the latest advancements in BPDCN treatment, including targeted therapies and promising chemotherapy regimens for better patient outcomes.

Explore the effective management of recurrent endometrial cancer with lenvatinib and pembrolizumab, emphasizing patient education and multidisciplinary care.

Explore the complexities of blastic plasmacytoid dendritic cell neoplasm, its challenges in diagnosis, and advancements in targeted therapies for better outcomes.

Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease

Artificial intelligence (AI) has the potential to transform biomarker testing in early-stage NSCLC by streamlining data analysis, improving interpretation of complex genomic profiles, and predicting actionable mutations from imaging or pathology data.

The KEYNOTE-775 study confirms long-term benefits of Lenvatinib and Pembrolizumab for recurrent endometrial cancer, showing sustained survival rates and efficacy.

This preview introduces the central themes of the upcoming Evolving Paradigms in Oncology program focused on targeted therapies and CELMoD agents in multiple myeloma. Dr. Nisha Joseph offers an early look at the questions that guide current treatment choices, the place of next generation CELMoD agents, and the way clinicians think about patient selection. The teaser sets the stage for a deeper conversation that will review clinical evidence, safety features, and practical points that influence decisions in daily practice. Viewers will gain an early sense of the topics and insights that will be explored in full during the complete expert discussion.

Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia at the 2025 ASH Meeting.

Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to complement or, in some cases, substitute for tissue-based testing.